Evidence map›Paper›PMID 30568951›Full record

ArticleWorld journal of clinical cases2018

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission.

Ryosuke Takano, Satoshi Osawa, Takahiro Uotani, Shinya Tani, Natsuki Ishida, Satoshi Tamura, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Takahisa Furuta and 2 more

Open access · diamondAbstract read
In one paragraph

Article in World journal of clinical cases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Review
  9. Review
  10. Astragaloside II alleviates the symptoms of experimental ulcerative colitisAmerican journal of translational research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ryosuke TakanoFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Satoshi OsawaDepartment of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan. sososawa@hama-med.ac.jp.
Takahiro UotaniFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Shinya TaniDepartment of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Natsuki IshidaFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Satoshi TamuraFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Mihoko YamadeFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Moriya IwaizumiDepartment of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Yasushi HamayaFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Takahisa FurutaCenter for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Hiroaki MiyajimaFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Ken SugimotoFirst Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
Hamamatsu University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo examine whether second generation of colon capsule endoscopy (CCE-2) is acceptable for assessing the severity of mucosal inflammation and evaluating mucosal healing using CCE-2 is able to predict outcome in ulcerative colitis (UC) patients, especially in clinical remission.

methodsA total of 30 consecutive UC patients in clinical remission were enrolled to undergo CCE-2. Clinical remission was defined as clinical activity index (CAI) ≤ 4 according to Rachmilewitz index. The rate of total colon observation and colon cleansing level were evaluated. Severity of mucosal inflammation in UC was assessed according to the Mayo endoscopic subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Relapse-free survival was assessed. Acceptability of CCE-2 was assessed using a questionnaire survey.

resultsThe rate of total colon observation within its battery life was 93.3%. The proportion of "excellent" plus "good" cleansing level was 73.3%. The rate of mucosal healing (MES 0, 1) assessed by CCE-2 was 77.0%. The relapse-free survival rate was significantly higher in MES 0, 1 than in MES 2, 3 (

conclusionCCE-2 is acceptable for assessing the severity of mucosal inflammation in UC patients, especially in clinical remission. Evaluating mucosal healing using CCE-2 was able to predict outcome.

Indexed as

Colon capsule endoscopyMayo endoscopic subscoreMucosal healingUlcerative colitisUlcerative Colitis Endoscopic Index of Severity

Identifiers

PMID30568951
PMCPMC6288494
OpenAlexW2904693977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.